MedTrace Logo

A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

NCT04825678 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.

Conditions

Interventions

DRUG

Erenumab

Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-11
Primary Completion
2023-09-28
Completion
2023-09-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04825678 on ClinicalTrials.gov